Daratumumab Use Prior to Kidney Transplant and T Cell–Mediated Rejection: A Case Report
Author:
Publisher
Elsevier BV
Subject
Nephrology
Reference6 articles.
1. Daratumumab depletes CD381 immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma;Krejcik;Blood,2016
2. Daratumumab induces mechanisms of immune activation through CD38+ NK cell targeting;Viola;Leukemia,2021
3. Daratumumab [package insert]. Horsham, PA. Janssen Biotech, Inc. 2015.
4. Daratumumab in sensitized kidney transplantation: potentials and limitations of experimental and clinical use;Kwun;J Am Soc Nephrol,2019
5. Daratumumab for treatment of antibody-mediated rejection after ABO-incompatible kidney transplantation;Spica;Case Rep Nephrol Dial,2019
Cited by 15 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Chronic Rejection After Kidney Transplantation;Transplantation;2024-08-28
2. The potential for therapeutic drug monitoring of belatacept and other biologicals in solid organ transplantation;British Journal of Clinical Pharmacology;2024-07-26
3. Renal Transplant Outcomes in Plasma Cell Dyscrasias and AL Amyloidosis after Treatment with Daratumumab;Journal of Clinical Medicine;2024-07-14
4. New Therapies for Highly Sensitized Patients on the Waiting List;Kidney360;2024-07-12
5. A Randomized Phase 2 Trial of Felzartamab in Antibody-Mediated Rejection;New England Journal of Medicine;2024-07-11
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3